Menu
ncarol.com
  • Home
  • Business
  • Real Estate
  • Health
  • Music
  • Services
  • Beauty
  • Finance
  • Non-profit
ncarol.com

SafeBreak® Vascular Cleared for Pediatrics
ncarol.com/10222999

Trending...
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
SafeBreak Vascular installed on a pediatric line SafeBreak Vascular installed on a pediatric line SafeBreak Vascular installed on a pediatric line Lineus Medical
FAYETTEVILLE, Ark. - ncarol.com -- Lineus Medical, a medical device company focused on reducing IV complications, announced that the company's flagship product, SafeBreak Vascular, has received clearance from the U.S. Food and Drug Administration (FDA) for use in pediatric patients. SafeBreak Vascular has been shown in adult clinical studies to reduce IV complications with its innovative breakaway technology1.

SafeBreak Vascular is the first breakaway device cleared by the FDA and proven to reduce IV complications in adults by 44%1. It fits between the IV tubing from the IV pump and the patient's IV access point at the arm. When there is a damaging force on the line, SafeBreak separates to protect the patient's IV. This innovative feature helps prevent accidental dislodgement of the catheter, as well as other IV complications caused by damaging forces on the IV line1. This is especially important for pediatric patients who may be more active, less inclined to follow instructions, and less aware of their surroundings.

More on ncarol.com
  • VDG Virtuoso Builds Independent Label (VDG Records) and PR Infrastructure
  • TheOneLofi2: New Home for Chill Lo-Fi Hip Hop Beats Launches on YouTube
  • VDG Virtuoso Establishes Independent Creative Infrastructure Focused on Long-Term Artist Development
  • eJoule Inc Participates in Silicon Dragon CES 2026
  • HBZBZL Unveils "Intelligent Ecosystem" Strategy: Integrating AI Analytics with Web3 Incubation

"We are incredibly proud to receive clearance from the FDA for the use of SafeBreak Vascular with pediatric patients," said Vance Clement, CEO of Lineus Medical. "SafeBreak provides a simple, effective solution for preventing IV complications, which reduces IV restarts and additional needlesticks for patients.  Now, it doesn't matter if the patient is 1 or 100 years old, SafeBreak is cleared for use on all peripheral IVs.  Our goal is to have a SafeBreak on every IV line, everywhere in the world, and this additional clearance lets us help one of the most vulnerable populations that needs it the most, our kids."

ABOUT LINEUS MEDICAL

Lineus Medical is the developer of a unique, patented, break-away technology that is designed to work with all types of medical tubing. Complications with feeding tubes, IV lines, urinary catheters and any other type of medical tubing may be reduced as breakaway devices separate to protect the patient. More information about Lineus Medical can be found on the company website:  www.lineusmed.com or you can follow the company on Twitter or LinkedIn.

1 Dipper Study Data on File

MKG-0194 REV 00

Contact
Vance Clement
***@lineusmed.com


Source: Lineus Medical

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • tukr box Ministries Launches Meal-Sharing Kit Partnership With Marry Me Marinara
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • Price Improvement on Luxurious Lāna'i Townhome with Stunning Ocean Views
  • Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
  • Elderhaus Receives 2025 Grant from The Endowment to Strengthen Services and Expand Community Impact
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Leimert Park Announces Weeklong Kwanzaa Festival & Kwanzaa Parade Celebrating Black History, Culture, and Community
  • Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
  • Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
  • Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
  • Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
  • UK Financial Ltd Launches U.S. Operations Following Delaware Approval
  • Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
  • Beycome Closes $2.5M Seed Round Led by InsurTech Fund
  • Tru by Hilton Columbia South Opens to Guests
  • Christy Sports donates $56K in new gear to SOS Outreach to help kids hit the slopes
  • "BigPirate" Sets Sail: A New Narrative-Driven Social Casino Adventure
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
_catLbl0 _catLbl1

Popular on ncarol.com

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 1451
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026 - 112
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
  • Kaltra Launches Next-Gen MCHEdesign With Full Integration Into MCHEselect — Instant Simulation & Seamless Microchannel Coil Workflow
  • Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform

Similar on ncarol.com

  • eJoule Inc Participates in Silicon Dragon CES 2026
  • A Well-Fed World, Youth Climate Save and PAN International Launch PHRESH: A Global Directory of Plant-Based Hunger Relief Organizations
  • Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence
  • Nextvisit Co-Founder Ryan Yannelli Identifies Six Critical Factors for Behavioral Health Providers Evaluating AI Scribes in 2026
  • Elderhaus Receives 2025 Grant from The Endowment to Strengthen Services and Expand Community Impact
  • CredHub and Real Property Management Join Forces to Empower Franchise Owners with Rental Payment Credit Reporting Solutions
  • Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
  • Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
  • Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute